AIVF

AIVF is a medical technology company empowering clinics with fertility intelligence. The company's flagship product is an AI software platform that helps accelerate data-driven, automated, and standardized processes for IVF patient care. AIVF's EMA platform is an AI-powered system that evaluates the viability of embryos during IVF procedures, analyzing biological data from Day Zero to Day 5 or Day 6, and scoring them based on their probability of successful implantation and pregnancy. This technology aims to standardize the embryo evaluation process across clinics, reducing human subjectivity and improving IVF success rates. AIVF also offers AIVF Genetics, a non-invasive AI tool for refining the genetic quality assessment of embryos. The company partners with leading clinics around the globe to advance research and innovation in reproductive medicine. AIVF was founded in 2018 in Tel Aviv, Israel, by Daniella Gilboa, a clinical embryologist, and Prof. Daniel Seidman, a reproductive endocrinologist and IVF expert. AIVF aims to improve the success rates of IVF treatments and shorten the time to pregnancy. In 2019, the company secured financial support from angel investors, venture capital firms, and grants from the Israel Innovation Authority and the European R&D program Eureka. In 2021, AIVF's EMA software received the CE Mark, indicating compliance with European health, safety, and environmental protection standards. The company is also GDPR and HIPAA-compliant, ensuring the privacy and security of patient data.